Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Originalsprog | Engelsk |
---|---|
Tidsskrift | The Lancet Oncology |
Vol/bind | 21 |
Udgave nummer | 12 |
Sider (fra-til) | 1574-1588 |
Antal sider | 15 |
ISSN | 1470-2045 |
DOI | |
Status | Udgivet - 1 dec. 2020 |
ID: 260747242